Result of Annual General Meeting
Cambridge, UK and Waltham, MA, 17 May 2023 – Abcam plc (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces the voting results from the Annual General Meeting (the “AGM”) held today. A total of 196,862,506 shares representing 85.7% of Abcam’s issued and outstanding voting capital (including withheld) were voted in connection with the meeting.
The votes were as follows:
180,306,403
99.94%
99,238
0.06%
16,456,865
8.36%
174,040,019
95.40%
8,387,468
4.60%
14,435,019
7.33%
179,459,110
99.19%
1,467,634
0.81%
15,935,762
8.09%
180,876,749
99.97%
47,249
0.03%
15,938,508
8.10%
171,602,332
96.27%
6,657,956
3.73%
18,602,218
9.45%
180,868,452
99.99%
15,522
0.01%
15,978,532
8.12%
173,249,012
95.02%
9,075,983
4.98%
14,537,511
7.38%
159,959,959
88.46%
20,861,003
11.54%
16,041,544
8.15%
161,230,904
89.17%
19,590,466
10.83%
16,041,136
8.15%
180,683,452
99.92%
137,918
0.08%
16,041,136
8.15%
179,114,658
99.06%
1,706,304
0.94%
16,041,544
8.15%
180,674,287
99.92%
147,533
0.08%
16,040,686
8.15%
180,796,348
99.99%
25,522
0.01%
16,040,636
8.15%
176,033,135
97.33%
4,826,779
2.67%
16,002,592
8.13%
176,443,735
97.56%
4,415,332
2.44%
16,003,439
8.13%
167,774,655
92.77%
13,083,811
7.23%
16,004,040
8.13%
180,863,563
99.99%
18,456
0.01%
15,980,487
8.12%
128,391,815
71.52%
51,119,075
28.48%
17,351,616
8.81%
The issued share capital (“ISC”) as of the date of the meeting was 229,723,147 Ordinary Shares.
The percentage of voting shares in favour and against is the percentage of shares voted and exclude shares on which votes were withheld.
About Abcam plc
As an innovator in reagents and tools, Abcam’s purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays and other research tools to address important targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life sciences, Abcam’s ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.
Abcam’s worldwide customer base of approximately 750,000 life science researchers uses Abcam’s antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.
Founded in 1998 and headquartered in Cambridge, UK, the Company has served customers in more than 130 countries. Abcam’s American Depositary Shares (ADSs) trade on the Nasdaq Global Market (Nasdaq: ABCM).
For more information, please visit www.abcam.com
Media contact: external.comms@abcam.com